Background 0 10 0 10 B-treatment
therapies 11 20 11 20 I-treatment
allowed 21 28 21 28 O
: 28 29 28 29 O
antimalarials 30 43 30 43 B-treatment
( 44 45 44 45 O
dose 45 49 45 49 B-clinical_variable
constant 50 58 50 58 I-clinical_variable
for 59 62 59 62 O
≥ 63 64 63 64 O
one 65 68 65 68 B-lower_bound
month 69 74 69 74 I-lower_bound
before 75 81 75 81 I-lower_bound
study 82 87 82 87 O
entry 88 93 88 93 O
and 94 97 94 97 O
during 98 104 98 104 O
16 105 107 105 107 B-upper_bound
weeks 108 113 108 113 I-upper_bound
of 114 116 114 116 O
trial 117 122 117 122 O
) 122 123 122 123 O
, 123 124 123 124 O
methotrexate 125 137 125 137 B-treatment
( 138 139 138 139 O
same 139 143 139 143 O
criteria 144 152 144 152 O
as 153 155 153 155 O
for 156 159 156 159 O
antimalarials 160 173 160 173 O
) 173 174 173 174 O
, 174 175 174 175 O
azathioprine 176 188 176 188 B-treatment
( 189 190 189 190 O
same 190 194 190 194 O
criteria 195 203 195 203 O
) 203 204 203 204 O
, 204 205 204 205 O
mycophenolate 206 219 206 219 B-treatment
( 220 221 220 221 O
same 221 225 221 225 O
criteria 226 234 226 234 O
) 234 235 234 235 O
, 235 236 235 236 O
leflunomide 237 248 237 248 B-treatment
( 249 250 249 250 O
same 250 254 250 254 O
criteria 255 263 255 263 O
) 263 264 263 264 O

Documented 0 10 265 275 O
positive 11 19 276 284 B-clinical_variable
ANA 20 23 285 288 I-clinical_variable
( 24 25 289 290 O
≥1:80 25 30 290 295 O
) 30 31 295 296 O
and/or 32 38 297 303 O
anti 39 43 304 308 B-treatment
- 43 44 308 309 I-treatment
dsDNA 44 49 309 314 I-treatment
during 50 56 315 321 O
course 57 63 322 328 O
of 64 66 329 331 O
SLE 67 70 332 335 B-chronic_disease

Inability 0 9 336 345 O
to 10 12 346 348 O
self 13 17 349 353 O
- 17 18 353 354 O
administer 18 28 354 364 O
subcutaneous 29 41 365 377 B-treatment
injections 42 52 378 388 I-treatment
, 52 53 388 389 O
to 54 56 390 392 O
comply 57 63 393 399 O
with 64 68 400 404 O
instructions 69 81 405 417 O
, 81 82 417 418 O
or 83 85 419 421 O
to 86 88 422 424 O
keep 89 93 425 429 O
appointments 94 106 430 442 O
for 107 110 443 446 O
study 111 116 447 452 O
visits 117 123 453 459 O

Meet 0 4 460 464 O
at 5 7 465 467 O
least 8 13 468 473 O
4 14 15 474 475 B-lower_bound
of 16 18 476 478 O
the 19 22 479 482 O
11 23 25 483 485 O
American 26 34 486 494 O
College 35 42 495 502 O
of 43 45 503 505 O
Rheumatology 46 58 506 518 O
( 59 60 519 520 O
ACR 60 63 520 523 O
) 63 64 523 524 O
1997 65 69 525 529 O
criteria 70 78 530 538 O
for 79 82 539 542 O
classification 83 97 543 557 O
of 98 100 558 560 O
SLE 101 104 561 564 O
( 105 106 565 566 O
see 106 109 566 569 O
Appendix 110 118 570 578 O
1).OR 119 124 579 584 O
meet 125 129 585 589 O
the 130 133 590 593 O
recent 134 140 594 600 O
classification 141 155 601 615 O
recommended 156 167 616 627 O
by 168 170 628 630 O
SLICC 171 176 631 636 O
( 177 178 637 638 O
Appendix 178 186 638 646 O
2 187 188 647 648 O
) 188 189 648 649 O
6 190 191 650 651 O

Men 0 3 652 655 B-gender
and 4 7 656 659 O
women 8 13 660 665 B-gender
, 13 14 665 666 O
at 15 17 667 669 O
least 18 23 670 675 O
18 24 26 676 678 B-lower_bound
years 27 32 679 684 I-lower_bound
of 33 35 685 687 O
age 36 39 688 691 B-age

Patients 0 8 692 700 O
requiring 9 18 701 710 O
> 19 20 711 712 O
20 20 22 712 714 B-lower_bound
mg 23 25 715 717 I-lower_bound
of 26 28 718 720 O
prednisone 29 39 721 731 B-treatment
daily 40 45 732 737 O

SLEDAI2 0 7 738 745 B-clinical_variable
K 7 8 745 746 I-clinical_variable
score 9 14 747 752 I-clinical_variable
≥4 15 17 753 755 O
indicating 18 28 756 766 O
active 29 35 767 773 O
disease 36 43 774 781 O

Subjects 0 8 782 790 O
with 9 13 791 795 O
BILAG 14 19 796 801 B-clinical_variable
A 20 21 802 803 O
in 22 24 804 806 O
any 25 28 807 810 O
system 29 35 811 817 O
outside 36 43 818 825 O
the 44 47 826 829 O
musculoskeletal 48 63 830 845 O
system 64 70 846 852 O

Subjects 0 8 853 861 O
with 9 13 862 866 O
a 14 15 867 868 O
history 16 23 869 876 O
of 24 26 877 879 O
cancer 27 33 880 886 B-cancer
within 34 40 887 893 O
the 41 44 894 897 O
last 45 49 898 902 B-upper_bound
five 50 54 903 907 I-upper_bound
years 55 60 908 913 I-upper_bound
( 61 62 914 915 O
other 62 67 915 920 O
than 68 72 921 925 O
non 73 76 926 929 B-cancer
- 76 77 929 930 I-cancer
melanoma 77 85 930 938 I-cancer
skin 86 90 939 943 I-cancer
cell 91 95 944 948 I-cancer
cancers 96 103 949 956 I-cancer
cured 104 109 957 962 O
by 110 112 963 965 O
local 113 118 966 971 B-treatment
resection 119 128 972 981 I-treatment
) 128 129 981 982 O

Subjects 0 8 983 991 O
with 9 13 992 996 O
active 14 20 997 1003 O
CNS 21 24 1004 1007 B-chronic_disease
disease 25 32 1008 1015 I-chronic_disease

Subjects 0 8 1016 1024 O
with 9 13 1025 1029 O
active 14 20 1030 1036 O
glomerulonephritis 21 39 1037 1055 B-chronic_disease
( 40 41 1056 1057 O
> 41 42 1057 1058 O
3 42 43 1058 1059 B-lower_bound
g 44 45 1060 1061 I-lower_bound
protein/24h 46 57 1062 1073 O
and/or 58 64 1074 1080 O
active 65 71 1081 1087 O
urine 72 77 1088 1093 O
sediment 78 86 1094 1102 O
) 86 87 1102 1103 O

Subjects 0 8 1104 1112 O
with 9 13 1113 1117 O
active 14 20 1118 1124 B-chronic_disease
infection 21 30 1125 1134 I-chronic_disease
requiring 31 40 1135 1144 O
oral 41 45 1145 1149 B-treatment
or 46 48 1150 1152 O
IV 49 51 1153 1155 B-treatment
antibiotics 52 63 1156 1167 I-treatment
within 64 70 1168 1174 O
one 71 74 1175 1178 B-upper_bound
month 75 80 1179 1184 I-upper_bound
of 81 83 1185 1187 O
first 84 89 1188 1193 O
dose 90 94 1194 1198 O
of 95 97 1199 1201 O
study 98 103 1202 1207 B-treatment
medication 104 114 1208 1218 I-treatment

Subjects 0 8 1219 1227 O
with 9 13 1228 1232 O
any 14 17 1233 1236 O
other 18 23 1237 1242 O
serious 24 31 1243 1250 O
disease 32 39 1251 1258 O
that 40 44 1259 1263 O
would 45 50 1264 1269 O
require 51 58 1270 1277 O
immunosuppressive 59 76 1278 1295 B-treatment
or 77 79 1296 1298 O
parenteral 80 90 1299 1309 B-treatment
anti 91 95 1310 1314 I-treatment
- 95 96 1314 1315 I-treatment
microbial 96 105 1315 1324 I-treatment
therapy 106 113 1325 1332 I-treatment
outside 114 121 1333 1340 O
the 122 125 1341 1344 O
study 126 131 1345 1350 O
protocol 132 140 1351 1359 O

Subjects 0 8 1360 1368 O
with 9 13 1369 1373 O
positive 14 22 1374 1382 O
quantiferon 23 34 1383 1394 B-treatment
Gold 35 39 1395 1399 I-treatment
test 40 44 1400 1404 I-treatment
in 45 47 1405 1407 O
the 48 51 1408 1411 O
absence 52 59 1412 1419 O
of 60 62 1420 1422 O
treatment 63 72 1423 1432 B-treatment
for 73 76 1433 1436 O
tuberculosis 77 89 1437 1449 B-chronic_disease

Subjects 0 8 1450 1458 O
with 9 13 1459 1463 O
positive 14 22 1464 1472 O
tests 23 28 1473 1478 O
for 29 32 1479 1482 O
active 33 39 1483 1489 B-chronic_disease
infection 40 49 1490 1499 I-chronic_disease
with 50 54 1500 1504 O
hepatitis 55 64 1505 1514 B-chronic_disease
B 65 66 1515 1516 I-chronic_disease
or 67 69 1517 1519 I-chronic_disease
C 70 71 1520 1521 I-chronic_disease
during 72 78 1522 1528 O
the 79 82 1529 1532 O
past 83 87 1533 1537 B-upper_bound
6 88 89 1538 1539 I-upper_bound
months 90 96 1540 1546 I-upper_bound
. 96 97 1546 1547 O
Any 98 101 1548 1551 O
confirmed 102 111 1552 1561 O
positive 112 120 1562 1570 O
test 121 125 1571 1575 O
for 126 129 1576 1579 O
HIV 130 133 1580 1583 B-chronic_disease
at 134 136 1584 1586 O
any 137 140 1587 1590 O
time 141 145 1591 1595 O
prior 146 151 1596 1601 O
to 152 154 1602 1604 O
entry 155 160 1605 1610 O
into 161 165 1611 1615 O
this 166 170 1616 1620 O
study 171 176 1621 1626 O

Treatment 0 9 1627 1636 B-treatment
with 10 14 1637 1641 I-treatment
any 15 18 1642 1645 I-treatment
other 19 24 1646 1651 I-treatment
immunomodulatory 25 41 1652 1668 I-treatment
biologic 42 50 1669 1677 I-treatment
or 51 53 1678 1680 I-treatment
cyclophosphamide 54 70 1681 1697 I-treatment
during 71 77 1698 1704 O
treatment 78 87 1705 1714 O
with 88 92 1715 1719 O
abatacept 93 102 1720 1729 O
is 103 105 1730 1732 O
not 106 109 1733 1736 O
allowed 110 117 1737 1744 O

Treatment 0 9 1745 1754 B-treatment
with 10 14 1755 1759 I-treatment
rituximab 15 24 1760 1769 I-treatment
within 25 31 1770 1776 O
the 32 35 1777 1780 O
past 36 40 1781 1785 B-upper_bound
6 41 42 1786 1787 I-upper_bound
months 43 49 1788 1794 I-upper_bound
( 50 51 1795 1796 O
B 51 52 1796 1797 O
cells 53 58 1798 1803 O
must 59 63 1804 1808 O
be 64 66 1809 1811 O
detectable 67 77 1812 1822 O
in 78 80 1823 1825 O
peripheral 81 91 1826 1836 O
blood 92 97 1837 1842 O
at 98 100 1843 1845 O
onset 101 106 1846 1851 O
of 107 109 1852 1854 O
treatment 110 119 1855 1864 B-treatment
with 120 124 1865 1869 O
study 125 130 1870 1875 O
biologic 131 139 1876 1884 O
) 139 140 1884 1885 O
, 140 141 1885 1886 O
belimumab 142 151 1887 1896 B-treatment
within 152 158 1897 1903 O
the 159 162 1904 1907 O
past 163 167 1908 1912 B-upper_bound
5 168 169 1913 1914 I-upper_bound
months 170 176 1915 1921 I-upper_bound
, 176 177 1921 1922 O
cyclophosphamide 178 194 1923 1939 B-treatment
within 195 201 1940 1946 O
the 202 205 1947 1950 O
past 206 210 1951 1955 B-upper_bound
3 211 212 1956 1957 I-upper_bound
months 213 219 1958 1964 I-upper_bound

Women 0 5 1965 1970 B-gender
of 6 8 1971 1973 O
child 9 14 1974 1979 O
bearing 15 22 1980 1987 O
potential 23 32 1988 1997 O
unwilling 33 42 1998 2007 B-contraception_consent
or 43 45 2008 2010 I-contraception_consent
unable 46 52 2011 2017 I-contraception_consent
to 53 55 2018 2020 I-contraception_consent
use 56 59 2021 2024 I-contraception_consent
an 60 62 2025 2027 I-contraception_consent
acceptable 63 73 2028 2038 I-contraception_consent
method 74 80 2039 2045 I-contraception_consent
to 81 83 2046 2048 O
avoid 84 89 2049 2054 O
pregnancy 90 99 2055 2064 B-pregnancy
for 100 103 2065 2068 O
the 104 107 2069 2072 O
entire 108 114 2073 2079 O
study 115 120 2080 2085 O
period 121 127 2086 2092 O
and 128 131 2093 2096 O
for 132 135 2097 2100 O
up 136 138 2101 2103 O
to 139 141 2104 2106 O
2 142 143 2107 2108 B-upper_bound
months 144 150 2109 2115 I-upper_bound
after 151 156 2116 2121 I-upper_bound
last 157 161 2122 2126 O
study 162 167 2127 2132 B-treatment
drug 168 172 2133 2137 I-treatment

Women 0 5 2138 2143 B-gender
of 6 8 2144 2146 O
childbearing 9 21 2147 2159 O
potential 22 31 2160 2169 O
must 32 36 2170 2174 O
use 37 40 2175 2178 B-contraception_consent
adequate 41 49 2179 2187 I-contraception_consent
method(s 50 58 2188 2196 I-contraception_consent
) 58 59 2196 2197 I-contraception_consent
of 60 62 2198 2200 I-contraception_consent
contraception 63 76 2201 2214 I-contraception_consent
to 77 79 2215 2217 O
avoid 80 85 2218 2223 O
pregnancy 86 95 2224 2233 B-pregnancy
throughout 96 106 2234 2244 O
the 107 110 2245 2248 O
study 111 116 2249 2254 O
and 117 120 2255 2258 O
for 121 124 2259 2262 O
up 125 127 2263 2265 O
to 128 130 2266 2268 O
2 131 132 2269 2270 B-upper_bound
months 133 139 2271 2277 I-upper_bound
after 140 145 2278 2283 I-upper_bound
last 146 150 2284 2288 O
study 151 156 2289 2294 B-treatment
drug 157 161 2295 2299 I-treatment
dose 162 166 2300 2304 O
. 166 167 2304 2305 O
They 168 172 2306 2310 O
must 173 177 2311 2315 O
have 178 182 2316 2320 O
a 183 184 2321 2322 O
negative 185 193 2323 2331 B-pregnancy
serum 194 199 2332 2337 I-pregnancy
or 200 202 2338 2340 I-pregnancy
urine 203 208 2341 2346 I-pregnancy
pregnancy 209 218 2347 2356 I-pregnancy
test 219 223 2357 2361 O
prior 224 229 2362 2367 O
to 230 232 2368 2370 O
the 233 236 2371 2374 O
start 237 242 2375 2380 O
of 243 245 2381 2383 O
study 246 251 2384 2389 O
medication 252 262 2390 2400 B-treatment

Women 0 5 2401 2406 B-gender
who 6 9 2407 2410 O
are 10 13 2411 2414 B-pregnancy
pregnant 14 22 2415 2423 I-pregnancy
or 23 25 2424 2426 O
breast 26 32 2427 2433 O
feeding 33 40 2434 2441 O

≥3 0 2 2442 2444 O
swollen 3 10 2445 2452 B-clinical_variable
and 11 14 2453 2456 I-clinical_variable
tender 15 21 2457 2463 I-clinical_variable
joints 22 28 2464 2470 I-clinical_variable
on 29 31 2471 2473 O
2 32 33 2474 2475 O
examinations 34 46 2476 2488 O
at 47 49 2489 2491 O
least 50 55 2492 2497 O
2 56 57 2498 2499 B-lower_bound
weeks 58 63 2500 2505 I-lower_bound
apart 64 69 2506 2511 O
and 70 73 2512 2515 O
no 74 76 2516 2518 O
more 77 81 2519 2523 O
than 82 86 2524 2528 O
8 87 88 2529 2530 B-upper_bound
weeks 89 94 2531 2536 I-upper_bound
apart 95 100 2537 2542 O

